BiotechTube

CT-01 + EVEROLIMUS

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatocellular Carcinoma (HCC)

Conditions

Hepatocellular Carcinoma (HCC)

Trial Timeline

May 26, 2025 → Apr 1, 2030

NCT ID
NCT06994572

About CT-01 + EVEROLIMUS

CT-01 + EVEROLIMUS is a phase 1 stage product being developed by Captor Therapeutics for Hepatocellular Carcinoma (HCC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06994572. Target conditions include Hepatocellular Carcinoma (HCC).

What happened to similar drugs?

5 of 20 similar drugs in Hepatocellular Carcinoma (HCC) were approved

Approved (5) Terminated (2) Active (14)
✅LenvatinibEisaiApproved
✅Epirubicin + lipiodolJohnson & JohnsonApproved
✅Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty OintmentBayerApproved
✅Xenetix-CT perfusion imagingGuerbetApproved
✅Gadoterate meglumineGuerbetApproved
🔄Ramucirumab + PlaceboEli LillyPhase 3
🔄Atezolizumab + Bevacizumab + TiragolumabChugai PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06994572Phase 1Recruiting

Competing Products

20 competing products in Hepatocellular Carcinoma (HCC)

See all competitors
ProductCompanyStageHype Score
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
26
Ramucirumab + PlaceboEli LillyPhase 3
40
ERY974 + Tocilicumab + Atezolizumab + BevacizumabChugai PharmaceuticalPhase 1
33
Atezolizumab + Bevacizumab + TiragolumabChugai PharmaceuticalPhase 3
44
GC33(RO5137382) + SorafenibChugai PharmaceuticalPhase 1
29
CS-1008 2 mg/kg + Sorafenib + CS-1008 6/2 mg/kg + CS-1008 6/6 mg/kg + CS-1008 4 mg/kg + CS-1008 6 mg/kgDaiichi SankyoPhase 2
35
Tivantinib + PlaceboDaiichi SankyoPhase 3
40
OSI-906 + PlaceboAstellas PharmaPhase 2
27
Enzalutamide + PlaceboAstellas PharmaPhase 2
35
Enzalutamide + Enzalutamide with SorafenibAstellas PharmaPhase 1
29
Recombinant oncolytic virus M1, anti PD-1 antibody, ApatinibSun PharmaceuticalPhase 1
25
Irinotecan + Sonidegib + SorafenibSun PharmaceuticalPhase 2
42
mFOLFOX7 combined with Camrelizumab and apatinibSun PharmaceuticalPhase 2
42
camrelizumab& apatinibSun PharmaceuticalPhase 2
31
LenvatinibEisaiPre-clinical
26
Lenvatinib PillEisaiPhase 2
39
Sorafenib + SorafenibEisaiPhase 1/2
32
LenvatinibEisaiPhase 2
42
Lenvatinib + NivolumabEisaiPhase 2
35
H3B-6527EisaiPhase 1
29